This retrospective study consisted of 11 eyes treated either with Iodine (I) -125 or Ruthenium (R) -106EB with a mean apical dose of 44Gy. There were five in group B (46%), three in group C (27%) and three in group D (27%). EB was primary in three eyes and eight were treated as secondary. Final visual acuity was better than 20/200 in 70% of cases, with globe preservation in nine cases. Local recurrence was reported in 18% of cases at a mean period of onset of 17.4 months. Two group D eyes recurred after secondary treatment and required enucleation. Radiation retinopathy occurred at a mean time of 17.4 months. Radiation-related complications included non-proliferative retinopathy in two eyes, proliferative retinopathy in three eyes and cataract in one eye. Recurrence free and ocular survival were found in 80% with overall survival of 100% over a five-year period after EB. The authors recommended a close follow-up period especially in the first six months post EB for recurrences and complications.
Episcleral brachytherapy (EB) for retinoblastoma (RB)
Top Of Page
Accreditations
Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2024 - Website by Gecko Agency